Key Takeaways TNDM reported a Q4 loss of 1 cent per share as revenues rose 15.1% to $290.4 million, beating estimates. Tandem Diabetes achieved record U.S. and international pump shipments, lifting gross margin to 57.7%. TNDM guided 2026 GAAP sales of $1.065B-$1.085B after posting $1.01B in 2025 non-GAAP revenues.Tandem Diabetes Care, Inc. (TNDM) posted a fourth-quarter 2025 loss of 1 cent per share compared with a loss of 44 cents a year ago. The figure surpassed the Zacks Consensus Estimate of a loss of 5 ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly.Top 5 Upgrades: Barclays upgraded Etsy (ETSY) to Overweight from Equal Weight with a price target of $72, up from $62. The firm sees the company's sale of Depop and its core business hovering around flattish after years of declines as a "tipping point" for Etsy, the firm tells investors in a research note. Argus upgraded Deck ...

Surpassed $1 billion in annual sales in 2025, driven by record fourth-quarter pump shipments and double-digit growth in both U.S. and international markets. Management is fundamentally reshaping the business model by transitioning to a 'pay-as-you-go' (PayGo) reimbursement structure in the pharmacy channel to reduce patient out-of-pocket barriers. The shift to pharmacy is expected to double the lifetime revenue per patient while streamlining the prescription process for healthcare providers and improv ...

Internationally, Q4 sales grew 17% year over year to $80 million on 11,000 pump shipments, aided by growth in both pump and supply shipments. Vosseller noted favorable foreign exchange, offset by $4 million tied to the company’s transition to direct operations that primarily affected pump sales. For 2025, total distributor destocking and inventory buyback impact was about $7 million, below the company’s earlier estimate of $10 million due to a partial timing shift into the first quarter of 2026.In the fourt ...

For the quarter ended December 2025, Tandem Diabetes Care, Inc. (TNDM) reported revenue of $290.38 million, up 15% over the same period last year. EPS came in at -$0.01, compared to -$0.44 in the year-ago quarter.The reported revenue represents a surprise of +5.21% over the Zacks Consensus Estimate of $276 million. With the consensus EPS estimate being -$0.05, the EPS surprise was +80.51%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectation ...

Core Viewpoint - Tandem Diabetes Care, Inc. reported a quarterly loss of $0.01 per share, outperforming the Zacks Consensus Estimate of a loss of $0.05, marking an earnings surprise of +80.51% compared to a loss of $0.44 per share a year ago [1][2] Financial Performance - The company posted revenues of $290.38 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 5.21% and showing an increase from $252.45 million in the same quarter last year [2] - Over the last four quarters, Tandem Diabetes Care has surpassed consensus revenue estimates four times [2] Stock Performance - Shares of Tandem Diabetes Care have declined approximately 13.8% since the beginning of the year, while the S&P 500 has gained 0.5% [3] - The current Zacks Rank for the stock is 3 (Hold), indicating expected performance in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.45 on revenues of $249.96 million, and for the current fiscal year, it is -$0.99 on revenues of $1.1 billion [7] - The trend of earnings estimate revisions is mixed ahead of the earnings release, which could influence future stock performance [6] Industry Context - The Medical - Instruments industry, to which Tandem Diabetes Care belongs, is currently ranked in the top 32% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Tandem Diabetes Care (NasdaqGM:TNDM) Q4 2025 Earnings call February 19, 2026 04:30 PM ET Company ParticipantsJoanne Wuensch - Managing DirectorJohn Sheridan - President and CEOJon Block - Managing DirectorLeigh Vosseller - EVP and CFOMathew Blackman - Managing DirectorMatt Taylor - Managing DirectorMike Kratky - Senior Managing Director of Medical Devices and Technology Equity ResearchShaymus Contorno - Equity Research AssociateSusan Morrison - EVP and Chief Administrative OfficerTravis Steed - Managing Dir ...

Financial Data and Key Metrics Changes - In 2025, Tandem achieved over $1 billion in worldwide sales, marking a 12% growth year-over-year, with U.S. sales increasing by 10% to $707 million and international sales growing by 15% to $308 million [17][19] - Q4 2025 saw record worldwide sales of $290 million, representing a 15% year-over-year growth, with U.S. Q4 sales increasing by 14% to $210 million [17][18] - Gross margin expanded by 3 percentage points to 54% for the full year, with the highest quarterly margin ever recorded at 58% [19][20] - Adjusted EBITDA was 11% of sales in Q4, a 10 percentage point improvement over the prior year, and the company reported its first positive operating margin since 2021 at 3% of sales in Q4 [20] Business Line Data and Key Metrics Changes - The U.S. saw more than 27,000 pump shipments in Q4, with renewals from loyal customers making up over half of the shipments [18] - Internationally, Q4 sales grew 17% year-over-year, delivering $80 million in sales and 11,000 pump shipments [19] Market Data and Key Metrics Changes - The company began direct commercial operations in the U.K., Switzerland, and Austria, with expectations for strong performance in these markets [9][27] - Direct sales represented approximately 5% of total international sales in 2025, expected to increase to about 15% in 2026 [28] Company Strategy and Development Direction - Tandem's strategy focuses on modernizing commercial operations, delivering new technology, and reshaping the business model to drive sustainable growth and profitability [8][13] - The company plans to accelerate pharmacy coverage for its products, transitioning to a pay-as-you-go reimbursement model to enhance customer access and reduce out-of-pocket costs [15][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving long-term objectives of accelerated sales growth, with a gross margin target of at least 65% and an operating margin of 25% [21] - The transition to a pay-as-you-go model is expected to moderate 2026 sales growth but is seen as a key driver for long-term value creation [23][30] Other Important Information - The company plans to launch multiple new products in 2026, including Mobi Tubeless, which is expected to redefine pump wearability [11][12] - The anticipated revenue for 2026 is projected to be in the range of $730 million to $745 million, incorporating pricing headwinds due to the new business model [26] Q&A Session Summary Question: Can you provide context on the expected growth rates for U.S. and international shipments? - Management indicated that overall revenue growth for the year is expected to be in the range of 10%-11%, with double-digit growth in shipments and a return to growth in new shipments [35] Question: What is the current status of pharmacy coverage and contracting? - Management confirmed contracts with major PBMs covering about 80% of lives, with formulary access currently at roughly one-third of lives covered [40] Question: Why is now the right time to implement the pay-as-you-go model? - Management noted that experience gained in Q4 and positive discussions with payers made this the right time for the transition [44] Question: How will the transition to direct sales impact revenue growth? - Management explained that while there are near-term headwinds, the transition is expected to create long-term benefits and improve market access [49] Question: What are the key levers for margin expansion moving forward? - Management highlighted pricing strategies and product cost reduction initiatives as significant levers for improving margins [56]

Financial Data and Key Metrics Changes - In 2025, Tandem Diabetes Care achieved over $1 billion in worldwide sales, marking a 12% growth year-over-year, with U.S. sales increasing by 10% to $707 million and international sales growing by 15% to $308 million [13][16] - Q4 2025 saw record worldwide sales of $290 million, representing a 15% year-over-year growth, with U.S. sales increasing by 14% to $210 million [14][15] - Gross margin expanded by 3 percentage points to 54% for the full year, with the highest quarterly margin ever recorded at 58% in Q4 [16][17] - Adjusted EBITDA was 11% of sales in Q4, a 10 percentage point improvement over the prior year, and the company reported its first positive operating margin since 2021 at 3% of sales in Q4 [17] Business Line Data and Key Metrics Changes - The U.S. market saw more than 27,000 pump shipments in Q4, with renewals from loyal customers making up over half of the shipments [15] - Internationally, Q4 sales grew 17% year-over-year, delivering $80 million in sales and 11,000 pump shipments [16] - Sales through the pharmacy channel nearly doubled from Q3, growing to $16 million or 7% of total U.S. sales in Q4 [15] Market Data and Key Metrics Changes - The company began direct commercial operations in the UK, Switzerland, and Austria, with expectations for strong sales productivity in these markets [6][23] - Direct sales represented approximately 5% of total international sales in 2025, expected to increase to about 15% in 2026 [24] Company Strategy and Development Direction - The company is focused on three key initiatives: modernizing commercial operations, delivering new technology, and reshaping the business model [4][5] - The transition to a pay-as-you-go reimbursement model is expected to drive market growth and profitability, with plans to increase pharmacy coverage for both t:slim X2 and Mobi platforms [10][11] - The company aims to maintain leadership in automated insulin delivery (AID) systems and plans to begin a pivotal trial for a fully closed loop algorithm later this year [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving long-term objectives of accelerated sales growth, with a gross margin target of at least 65% and an operating margin of 25% [18] - The transition to the pay-as-you-go model is anticipated to moderate sales growth in 2026 but is expected to create a more predictable revenue stream over time [19][21] - Management highlighted the importance of pump shipments as a key indicator of progress in growing the market while expanding margins [19] Other Important Information - The company exited 2025 with nearly $300 million in total cash and investments, generating free cash flow in both Q3 and Q4 [17] - The anticipated revenue headwinds from the pay-as-you-go model are expected to be most pronounced in 2026, with a projected U.S. sales range of $730 million to $745 million [22] Q&A Session Summary Question: Can you provide context on the expected growth rates for U.S. and international shipments? - Management indicated that overall revenue growth for the year is expected to be in the line of 10-11%, with double-digit growth in shipments [32] Question: What is the current status of pharmacy coverage and contracting? - Management confirmed contracts with major PBMs covering about 80% of lives, with formulary access currently at roughly a third [40] Question: Why is now the right time for the pay-as-you-go model? - Management stated that the experience gained in Q4 and positive conversations with payers made this the right time for the transition [44] Question: How will the transition to direct sales impact revenue? - Management explained that while there are headwinds from the transition, the long-term benefits of direct sales and pricing premiums are expected to outweigh these challenges [77] Question: What are the expected impacts of the pharmacy shift on the P&L? - Management noted that the headwinds from the pay-as-you-go model will be more pronounced in 2026, but the transition is expected to lead to significant revenue growth in subsequent years [68]

Earnings 2025 FY & Q4 February 19, 2026 ››› Page 1 © 2025 Tandem Diabetes Care, Inc. All Rights Reserved Disclaimers & Safe Harbor CAUTIONARY NOTES REGARDING FORWARD LOOKING-STATEMENTS Certain statements in this presentation constitute forward-looking statements, including, without limitation, statements about: the perceived advantages of our products relative to competitive products and technologies; our anticipated growth and other measures of future operating results and financial performance; the develo ...